Cervical Spine Bone Graft Gains FDA Go-Ahead
This article was originally published in The Gray Sheet
Executive Summary
Cerapedics' i-Factor peptide-enhanced bone graft will be used to treat degenerative cervical disc disease, the first bone graft product PMA-approved for that indication, the company says.
You may also be interested in...
High Court Won’t Hear InFuse Off-Label Preemption Case
The case would have tested whether manufacturers could be held liable if an FDA-approved device injured a patient when the product was employed for an off-label, unapproved use. The Oklahoma Federal Court and the 10th Circuit Court of Appeals had both previously ruled in industry’s favor.
Wright Brings New Biologic To U.S. Ortho Space With Augment Approval
The Augment biologic-based device was approved for use in ankle and hindfoot fusions after overcoming multiple regulatory challenges.
New Product Briefs
FDA approves St. Jude's Brio deep brain stimulator for Parkinson's and essential tremor. The agency also approves Aesculap's activL artificial disc and said Cerapedics' i-Factor bone graft review will proceed without an advisory panel.